UK shares ended the week at their highest level since February 2020 on higher commodity prices and more corporate activity, despite a disappointing US jobs report earlier in the session.
The gains were partly fueled by copper prices hitting an all-time high, having rallied by more than a third this year, with iron ore and other metals also posting strong gains. Oil prices were also buoyant with Brent futures trading around $68 per barrel.
At the close the FTSE 100 index of leading shares was up 54 points or 0.75% at 7,130 led by miners, banks and industrials.
The advance would have been stronger were sterling not also advancing to $1.391 against the dollar, putting pressure on heavyweight consumer stocks with large overseas earnings.
Somewhat surprisingly, what should have been a big market-moving event - the biggest disappointment in the US non-farm jobs report since the late 1990s - turned out to have very little effect on prices
MORE M&A ACTIVITY
Adding to the upward impetus to markets, there was more corporate activity with UK companies being targeted.
Shares in property developer St. Modwen (SMP) jumped 20% to 537p after it said it had received a non-binding proposal from funds managed by Blackstone regarding a possible cash offer of 542p per share, representing a 21.1% premium to the prior closing price.
The company said it was working with Blackstone to complete the required due diligence as soon as possible.
Meanwhile, shares in aerospace parts maker Meggitt (MGGT) climbed 7.5% to 495p on unconfirmed reports US rival Woodward Inc was preparing a bid for the UK firm.
In March, Megitt posted a 50% drop in operating profits for 2020 on the collapse of the civil aerospace market, but said it could return to profit growth in 2021 provided there were no new travel restrictions.
OTHER CORPORATE NEWS
Pharmaceutical firm AstraZeneca (AZN) said a phase three trial of its lung cancer drug Imfinzi treated in combination with monoclonal antibody tremelimumab and chemotherapy demonstrated a progression-free survival benefit.
However, the combination of Imfinzi and chemotherapy combination didn’t show a statistically significant improvement in overall survival. The shares added 0.7% to £77.35.
This reflected a 23% reduction in occupancy, with the rate sustained at about 80% of 2019 levels. The company said there was a notable pick-up in demand in March, particularly in the US and China, which continued into April. The shares put on 1.4% to £51.16.
This led to a reduced operating loss of €1.1 billion compared with €1.8 billion in 2020.
Plans for the second quarter capacity are running at around 25% of 2019 levels. Liquidity increased to €10.5 billion from €10.3 billion in the previous quarter driven by cost reductions and financing initiatives. The shares climbed 2.6% to 213p.
Gyroscope said it had postponed its public offering 'in light of current market conditions'.
Having shot 50p or 23% higher to 285p during the day, the shares closed down 4% at 225p on a small sell order.
Group sales increased by around 11% to £21.8 million driven by demand for coronavirus related products. The company also said first quarter revenues were 8% higher.
The company said its consistent focus on enhancing the firm's capabilities and strengthening client relationships had contributed to an excellent and broad-based first-half performance, and it had plenty of deals in the pipeline. Shares added 1.8% to 398p.
FOR A LIST OF FTSE 100 RISERS AND FALLERS SEE HERE